Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Gets OK To Discuss Confirmatory Study Plans At Avastin Hearing

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA hearing officer Karen Midthun rejects the Center for Drug Evaluation and Research's request to bar evidence on discussions over a new study of Avastin in first-line metastatic breast cancer.
Advertisement

Related Content

Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer
Avastin Breast Cancer Dispute Centers On “Magnitude Of Benefit” Questions
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
CDER Seeks To Limit Evidence On Future Avastin Studies At June Hearing
An Avastin Loophole: Hamburg Could Decide To Retain Approval During Confirmatory Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS072298

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel